Allergan bags an early-stage gene therapy in $60M RetroSense buyout
While Allergan’s acquisitive CEO Brent Saunders was mapping out a new commitment to shun predatory pricing, he simultaneously threw in the latest in a series of bolt-on buyouts.
This time, Saunders has decided to pay $60 million up front to acquire a small gene therapy player based in Ann Arbor, MI. RetroSense Therapeutics has been attracting attention for its work using a gene therapy to restore light sensitivity to the retina in an attempt to restore the sight of people who have been blinded by retinitis pigmentosa.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.